ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 1, 2005, Pages

  Pestalozzi, B C ^a,e   Luporsi Gely, E ^b,e   Jost, L M ^c,e   Bergh, J ^d,e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CENTRE ALEXIS VAUTRIN   (France)

^c KANTONSSPITAL   (Switzerland)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ESMO Guidelines Task Force   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; HEMOPOIETIC GROWTH FACTOR; LETROZOLE; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ARTICLE; BONE DISEASE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARDIOVASCULAR DISEASE; DRUG EFFICACY; ECHOGRAPHY; EUROPEAN UNION; FOLLOW UP; GEOGRAPHY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LUNG TOXICITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MEDICAL SOCIETY; OVARIECTOMY; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SYSTEMIC THERAPY;

EID: 21044446122     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi825     Document Type: Article

References (17)

1. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332: 901-906.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
4. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: International Consensus Panel on the Primary Treatment of Early Breast Cancer. Ninth International Conference on Primary Therapy of Early Breast Cancer. J Clin Oncol 2003; 17: 3357-3365.
5. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
6. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-1196.
7. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000; 355: 1757-1770.
8. Recht A, Edge SB, Solin LJ et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1539-1569.
9. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.
10. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding wequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
11. Raimund Jakesz, Hubert Hausmaninger, Ernst Kubista et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002; 20: 4621-4627.
12. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
13. Greene FL, Balch CM, Fleming ID, et al. (eds): In AJCC (American Joint Committee on Cancer) Cancer Staging Handbook: TNM Classification of Malignant Tumors, sixth edition. New York: Springer-Verlag 2002.
14. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
15. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
16. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
17. Winer EP, Hudis C, Burstein HJ et al. ASCO technology assessment on the use of aromatase inhibitors as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-629.